Literature DB >> 30410211

Drugs for benign prostatic hypertrophy.

Manasi Jiwrajka1,2,3, William Yaxley1,2,3, Sachinka Ranasinghe1,2,3, Marlon Perera1,2,3, Matthew J Roberts1,2,3, John Yaxley1,2,3.   

Abstract

Entities:  

Keywords:  5-alpha-reductase inhibitors; alpha blockers; benign prostatic hyperplasia

Year:  2018        PMID： 30410211      PMCID： PMC6202296          DOI： 10.18773/austprescr.2018.045

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  28 in total

1.  Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.

Authors:  A E Thigpen; R I Silver; J M Guileyardo; M L Casey; J D McConnell; D W Russell
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

2.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

3.  A practical approach to the management of lower urinary tract symptoms among men.

Authors:  Henry H Woo; Michael P Gillman; Robert Gardiner; Villis Marshall; William J Lynch
Journal:  Med J Aust       Date:  2011-07-04       Impact factor: 7.738

Review 4.  The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

Authors:  Leonard S Marks; Gerald L Andriole; John M Fitzpatrick; Claude C Schulman; Claus G Roehrborn
Journal:  J Urol       Date:  2006-09       Impact factor: 7.450

Review 5.  A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.

Authors:  Michael J Naslund; Martin Miner
Journal:  Clin Ther       Date:  2007-01       Impact factor: 3.393

6.  Quality of life and sexual function in patients with benign prostatic hyperplasia.

Authors:  Reginald C Bruskewitz
Journal:  Rev Urol       Date:  2003

7.  Alpha blockers for the treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2007

8.  Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research.

Authors:  J D McConnell; M J Barry; R C Bruskewitz
Journal:  Clin Pract Guidel Quick Ref Guide Clin       Date:  1994-02

9.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Authors:  G L Andriole; H A Guess; J I Epstein; H Wise; D Kadmon; E D Crawford; P Hudson; C L Jackson; N A Romas; L Patterson; T J Cook; J Waldstreicher
Journal:  Urology       Date:  1998-08       Impact factor: 2.649

Review 10.  The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.

Authors:  Jason Gandhi; Steven J Weissbart; Noel L Smith; Steven A Kaplan; Gautam Dagur; Anna Zumbo; Gargi Joshi; Sardar Ali Khan
Journal:  Transl Androl Urol       Date:  2017-04
View more
  4 in total

1.  Efficacy and tolerability of Roystonea regia lipid extract (D-004) and terazosin in men with symptomatic benign prostatic hyperplasia: a 6-month study.

Authors:  Raúl Guzmán; Julio C Fernández; Manuel Pedroso; Lilia Fernández; José Illnait; Sarahí Mendoza; Ana T Quiala; Zunilda Rodríguez; Jilma Mena; Aylim Rodíguez; Marbelis Campos; Carlos Sánchez; Yanet Alvarez; Gladys Jiménez
Journal:  Ther Adv Urol       Date:  2019-06-11

2.  Neferine improves oxidative stress and apoptosis in benign prostate hyperplasia via Nrf2-ARE pathway.

Authors:  Nabila Jahan; Apu Chowdhury; Ting Li; Ke Xu; Fen Wei; Sicen Wang
Journal:  Redox Rep       Date:  2021-12       Impact factor: 4.412

3.  A phytosterol-enriched saw palmetto supercritical CO2 extract ameliorates testosterone-induced benign prostatic hyperplasia by regulating the inflammatory and apoptotic proteins in a rat model.

Authors:  Heggar V Sudeep; Karempudi Venkatakrishna; Ballal Amrutharaj; Kodimule Shyamprasad
Journal:  BMC Complement Altern Med       Date:  2019-10-17       Impact factor: 3.659

4.  Bladder infusion versus standard catheter removal for trial of void: a systematic review and meta-analysis.

Authors:  Joshua Makary; Kevin Phan; George McClintock; Marinelle Doctor; David Habashy; Sean Heywood; Steve P McCombie; Mohan Arianayagam; Bertram Canagasingham; Richard Ferguson; Ahmed Goolam; Mohamed Khadra; Raymond Ko; Celi Varol; Matthew Winter; Matthew J Roberts
Journal:  World J Urol       Date:  2020-08-14       Impact factor: 4.226
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.